Department of Pathology, University of Miami, Miami, Florida, USA
Department of Pathology, University of Miami, Miami, Florida, USA.
J Virol. 2019 Feb 19;93(5). doi: 10.1128/JVI.01626-18. Print 2019 Mar 1.
Approximately 50% of rhesus macaques (RMs) expressing the major histocompatibility complex class I (MHC-I) allele spontaneously control chronic-phase viremia after infection with the pathogenic simian immunodeficiency virus mac239 (SIVmac239) clone. CD8 T-cell responses in these animals are focused on immunodominant Mamu-B08-restricted SIV epitopes in Vif and Nef, and prophylactic vaccination with these epitopes increases the incidence of elite control in SIVmac239-infected -positive ( ) RMs. Here we evaluated if robust vaccine-elicited CD8 T-cell responses against Vif and Nef can prevent systemic infection in RMs following mucosal SIV challenges. Ten RMs were vaccinated with a heterologous prime/boost/boost regimen encoding Vif and Nef, while six sham-vaccinated MHC-I-matched RMs served as the controls for this experiment. Vaccine-induced CD8 T cells against Mamu-B08-restricted SIV epitopes reached high frequencies in blood but were present at lower levels in lymph node and gut biopsy specimens. Following repeated intrarectal challenges with SIVmac239, all control RMs became infected by the sixth SIV exposure. By comparison, four vaccinees were still uninfected after six challenges, and three of them remained aviremic after 3 or 4 additional challenges. The rate of SIV acquisition in the vaccinees was numerically lower (albeit not statistically significantly) than that in the controls. However, peak viremia was significantly reduced in infected vaccinees compared to control animals. We found no T-cell markers that distinguished vaccinees that acquired SIV infection from those that did not. Additional studies will be needed to validate these findings and determine if cellular immunity can be harnessed to prevent the establishment of productive immunodeficiency virus infection. It is generally accepted that the antiviral effects of vaccine-induced classical CD8 T-cell responses against human immunodeficiency virus (HIV) are limited to partial reductions in viremia after the establishment of productive infection. Here we show that rhesus macaques (RMs) vaccinated with Vif and Nef acquired simian immunodeficiency virus (SIV) infection at a lower (albeit not statistically significant) rate than control RMs following repeated intrarectal challenges with a pathogenic SIV clone. All animals in the present experiment expressed the elite control-associated major histocompatibility complex class I (MHC-I) molecule Mamu-B*08 that binds immunodominant epitopes in Vif and Nef. Though preliminary, these results provide tantalizing evidence that the protective efficacy of vaccine-elicited CD8 T cells may be greater than previously thought. Future studies should examine if vaccine-induced cellular immunity can prevent systemic viral replication in RMs that do not express MHC-I alleles associated with elite control of SIV infection.
大约 50%的表达主要组织相容性复合体 I 类 (MHC-I) 等位基因的恒河猴 (RMs) 在感染致病性猿猴免疫缺陷病毒 mac239 (SIVmac239) 克隆后,可自发控制慢性期病毒血症。这些动物中的 CD8 T 细胞反应集中在 Vif 和 Nef 中免疫优势的 Mamu-B08 限制性 SIV 表位上,预防性接种这些表位可增加 SIVmac239 感染阳性 ( ) RMs 中精英控制的发生率。在这里,我们评估了在粘膜 SIV 挑战后,针对 Vif 和 Nef 的强大疫苗诱导的 CD8 T 细胞反应是否可以预防 RMs 的全身感染。10 只 RMs 用编码 Vif 和 Nef 的异源初免/加强/加强方案进行了疫苗接种,而 6 只假疫苗接种的 MHC-I 匹配 RMs 作为该实验的对照。针对 Mamu-B08 限制性 SIV 表位的疫苗诱导的 CD8 T 细胞在血液中达到了高频率,但在淋巴结和肠道活检标本中的水平较低。在重复经直肠 SIVmac239 挑战后,所有对照 RMs 在第六次 SIV 暴露时均被感染。相比之下,在六次挑战后,有 4 名疫苗接种者仍未感染,其中 3 名在 3 或 4 次额外挑战后仍未出现病毒血症。疫苗接种者的 SIV 获得率虽然(但无统计学意义)低于对照组,但感染疫苗接种者的病毒血症峰值明显低于对照组。我们没有发现可区分接种疫苗后获得 SIV 感染与未感染的 T 细胞标志物。需要进一步的研究来验证这些发现,并确定细胞免疫是否可用于预防产生性免疫缺陷病毒感染。人们普遍认为,疫苗诱导的针对人类免疫缺陷病毒 (HIV) 的经典 CD8 T 细胞反应的抗病毒作用仅限于在建立有活性的感染后,部分降低病毒血症。在这里,我们表明,用 Vif 和 Nef 疫苗接种的恒河猴 (RMs) 在经直肠重复接种致病性 SIV 克隆后,与对照 RMs 相比,以较低的(尽管无统计学意义)速度获得了猴免疫缺陷病毒 (SIV) 感染。本实验中的所有动物均表达与 SIV 感染精英控制相关的主要组织相容性复合体 I 类 (MHC-I) 分子 Mamu-B*08,该分子结合 Vif 和 Nef 中的免疫优势表位。尽管初步的,但这些结果提供了令人兴奋的证据,表明疫苗诱导的 CD8 T 细胞的保护效力可能比以前认为的更大。未来的研究应检查疫苗诱导的细胞免疫是否可以预防不表达与 SIV 感染精英控制相关的 MHC-I 等位基因的 RMs 中的全身病毒复制。